[go: up one dir, main page]

CR20140318A - Composiciones intranasales de dexmedetomidina y métodos de uso de ellas - Google Patents

Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Info

Publication number
CR20140318A
CR20140318A CR20140318A CR20140318A CR20140318A CR 20140318 A CR20140318 A CR 20140318A CR 20140318 A CR20140318 A CR 20140318A CR 20140318 A CR20140318 A CR 20140318A CR 20140318 A CR20140318 A CR 20140318A
Authority
CR
Costa Rica
Prior art keywords
dexmedetomidine
methods
intranasal compositions
intranasal
compositions
Prior art date
Application number
CR20140318A
Other languages
English (en)
Inventor
Geraldine A Henwood
Randall J Mack
Jr John Joseph Koleng
Christopher T Sharr
Charles Alexander Freyer
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of CR20140318A publication Critical patent/CR20140318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee formulaciones intranasales que comprenden dexmedetomidina, o una sal farmacéuticamente aceptable de ella y sus usos.
CR20140318A 2011-12-11 2014-07-03 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas CR20140318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11
PCT/US2012/068988 WO2013090278A2 (en) 2011-12-11 2012-12-11 Intranasal dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20140318A true CR20140318A (es) 2014-10-28

Family

ID=48613351

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140318A CR20140318A (es) 2011-12-11 2014-07-03 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Country Status (20)

Country Link
US (2) US9795559B2 (es)
EP (2) EP3406247A1 (es)
JP (2) JP6268100B2 (es)
KR (1) KR102190009B1 (es)
CN (1) CN104470516A (es)
AU (2) AU2012352528B9 (es)
BR (1) BR112014019171A8 (es)
CA (1) CA2858721C (es)
CL (1) CL2014001515A1 (es)
CO (1) CO7000773A2 (es)
CR (1) CR20140318A (es)
DO (1) DOP2014000123A (es)
EC (1) ECSP14007644A (es)
IL (1) IL232977B (es)
MX (1) MX367286B (es)
PE (1) PE20142314A1 (es)
PH (1) PH12014501273A1 (es)
RU (1) RU2692245C2 (es)
SG (2) SG11201403094TA (es)
WO (1) WO2013090278A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074079B2 (en) 2010-06-16 2015-07-07 Cargill, Incorporated Starch-based compositions for latex replacement
MX367286B (es) * 2011-12-11 2019-08-13 Recro Pharma Inc Composiciones de dexmedetomidina intranasal y sus metodos de uso.
EP3049059B1 (en) * 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
CN110585173A (zh) 2013-10-07 2019-12-20 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
DK3562486T3 (da) 2016-12-31 2024-06-10 Bioxcel Therapeutics Inc Anvendelse af sublingual dexmedetomidin til behandling af agitation
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2020259440A1 (zh) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
MX2023007998A (es) * 2021-01-04 2023-08-08 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina.
CN118217243A (zh) * 2021-03-29 2024-06-21 四川普锐特药业有限公司 一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DK1516639T4 (en) 1990-12-05 2015-06-29 Gen Hospital Corp Use of NO to treat persistent pulmonary hypertension in newborns
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ES2244998T5 (es) 1996-05-29 2009-06-15 Delsitech Oy Oxidos solubles para aplicaciones biologicas.
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
DE69924536T2 (de) 1998-10-20 2006-02-16 Omeros Corp., Seattle Spülende lösung und methoden zur hemmung von schmerzen und entzündungen
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US20030022926A1 (en) 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
CA2510199A1 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
KR101370096B1 (ko) 2006-02-13 2014-03-04 오리엔트 파르마 (사모아) 컴퍼니 리미티드 타액 분비 과다증 치료를 위한 알파-2 수용체 작용제(클로니딘) 및 항-무스카린제(옥시부티닌)의 복합물
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008003093A2 (en) 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法
WO2009086055A1 (en) 2007-12-21 2009-07-09 Schering-Plough Healthcare Products, Inc. Enhancing photostabilization of oxymetazoline
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
MX2012001139A (es) * 2009-07-27 2012-07-30 Trigemina Inc Metodos para el tratamiento del dolor.
NZ601195A (en) * 2010-01-08 2015-02-27 Recro Pharma Inc Topical transdermal dexmedetomidine compositions and methods of use thereof
MX367286B (es) * 2011-12-11 2019-08-13 Recro Pharma Inc Composiciones de dexmedetomidina intranasal y sus metodos de uso.

Also Published As

Publication number Publication date
SG10201604653TA (en) 2016-07-28
HK1203049A1 (en) 2015-10-16
ECSP14007644A (es) 2015-11-30
NZ626999A (en) 2016-07-29
CN104470516A (zh) 2015-03-25
EP3406247A1 (en) 2018-11-28
PE20142314A1 (es) 2015-01-23
BR112014019171A8 (pt) 2017-07-11
EP2787970A4 (en) 2015-10-28
WO2013090278A2 (en) 2013-06-20
MX2014006961A (es) 2014-09-22
JP2015513309A (ja) 2015-05-07
US9795559B2 (en) 2017-10-24
KR20140107329A (ko) 2014-09-04
AU2018200591A1 (en) 2018-02-15
JP2018030850A (ja) 2018-03-01
AU2012352528B9 (en) 2017-11-02
DOP2014000123A (es) 2014-12-31
MX367286B (es) 2019-08-13
JP6505177B2 (ja) 2019-04-24
EP2787970B1 (en) 2018-04-11
JP6268100B2 (ja) 2018-01-24
CO7000773A2 (es) 2014-07-21
IL232977B (en) 2019-01-31
BR112014019171A2 (es) 2017-06-20
CA2858721A1 (en) 2013-06-20
CA2858721C (en) 2021-03-16
US20180055764A1 (en) 2018-03-01
SG11201403094TA (en) 2014-10-30
PH12014501273A1 (en) 2014-09-08
US20130178465A1 (en) 2013-07-11
AU2012352528A1 (en) 2014-07-10
AU2012352528B2 (en) 2017-10-26
AU2018200591B2 (en) 2018-11-29
CL2014001515A1 (es) 2014-12-05
WO2013090278A3 (en) 2014-12-24
KR102190009B1 (ko) 2020-12-15
EP2787970A2 (en) 2014-10-15
RU2014128343A (ru) 2016-01-27
RU2692245C2 (ru) 2019-06-24
US10682311B2 (en) 2020-06-16
IL232977A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20150462A (es) Inhibidores de erk y sus usos
CR20160419A (es) Nuevos compuestos biciclicos
DK2814504T3 (da) Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
MX372661B (es) Anticuerpos anti-htra1 y metodos de uso.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
BR112015020053B8 (pt) Composições para cuidado oral
MX2013008559A (es) Derivados de leptina.
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis